The Role of PPARs in Disease.

Alzheimer’s disease (AD) addiction adipogenesis alcohol animal models cancer cellular metabolism fibrosis human studies hypertrophic obesity inflammation insulin-resistance kidney ligands lipidomics nicotine non-alcoholic fatty liver disease (NAFLD) non-alcoholic steatohepatitis (NASH) opioids peroxisome proliferator-activated receptor-γ coactivator-1α peroxisome proliferator-activated receptors (PPARs) pharmacology proliferation psychostimulants toxicology tumor angiogenesis vascular

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
28 10 2020
Historique:
received: 23 10 2020
accepted: 25 10 2020
entrez: 31 10 2020
pubmed: 1 11 2020
medline: 22 6 2021
Statut: epublish

Résumé

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that function as ligand-activated transcription factors. They exist in three isoforms: PPARα, PPARβ/δ, and PPARγ. For all PPARs, lipids are endogenous ligands, linking them directly to metabolism. PPARs form heterodimers with retinoic X receptors, and upon ligand binding, they modulate the gene expression of downstream target genes, depending on the presence of co-repressors or co-activators. This results in a complex, cell type-specific regulation of proliferation, differentiation, and cell survival. PPARs are linked to metabolic disorders and are interesting pharmaceutical targets. PPARα and PPARγ agonists are already in clinical use for the treatment of hyperlipidemia and type 2 diabetes, respectively. More recently, PPARβ/δ activation came into focus as an interesting novel approach for the treatment of metabolic syndrome and associated cardiovascular diseases; however, this has been limited due to the highly controversial function of PPARβ/δ in cancer. This Special Issue of

Identifiants

pubmed: 33126411
pii: cells9112367
doi: 10.3390/cells9112367
pmc: PMC7692109
pii:
doi:

Substances chimiques

Ligands 0
Peroxisome Proliferator-Activated Receptors 0

Types de publication

Editorial Introductory Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Cells. 2020 May 14;9(5):
pubmed: 32422896
Cell. 1999 Apr 16;97(2):161-3
pubmed: 10219237
Cell Metab. 2017 May 2;25(5):1186-1193.e4
pubmed: 28467934
Pharmacol Ther. 2010 Mar;125(3):423-35
pubmed: 20026355
Cells. 2020 Jul 08;9(7):
pubmed: 32650421
Int J Mol Sci. 2020 Aug 10;21(16):
pubmed: 32785018
Cells. 2020 May 21;9(5):
pubmed: 32455814
Cells. 2020 Aug 11;9(8):
pubmed: 32796716
Cells. 2020 Oct 03;9(10):
pubmed: 33022986
Cells. 2020 May 12;9(5):
pubmed: 32408505
Cells. 2020 May 04;9(5):
pubmed: 32375405
PPAR Res. 2016;2016:7631085
pubmed: 27057154
Cell. 2003 Apr 18;113(2):159-70
pubmed: 12705865
Future Cardiol. 2017 May;13(3):259-278
pubmed: 28581332
Future Cardiol. 2017 May;13(3):279-296
pubmed: 28581362
Cells. 2020 Apr 29;9(5):
pubmed: 32365470
Cells. 2020 Feb 03;9(2):
pubmed: 32028670
Cells. 2019 Dec 12;8(12):
pubmed: 31842402
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931

Auteurs

Nicole Wagner (N)

Université Côte d'Azur, CNRS, INSERM, iBV, 06107 Nice, France.

Kay-Dietrich Wagner (KD)

Université Côte d'Azur, CNRS, INSERM, iBV, 06107 Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH